Neumora Therapeutics (NMRA) Current Leases (2022 - 2026)

Neumora Therapeutics' Current Leases history runs 5 years deep, the most recent figure standing at $291000.0 for Q1 2026.

• On a quarterly basis, Current Leases fell 68.98% year-over-year to $291000.0 in Q1 2026; TTM through Mar 2026 was $291000.0, a 68.98% decrease from a year earlier, with the FY2025 full-year figure at $284000.0, down 84.67% from the prior year.
• Current Leases improved to $291000.0 in Q1 2026 per NMRA's latest filing, from $284000.0 in the prior quarter.
• Across five years, Current Leases topped out at $3.6 million in Q2 2024 and bottomed at $171000.0 in Q2 2025.
• The 5-year median for Current Leases is $2.3 million (2024), against an average of $2.0 million.
• Across the five-year window, Current Leases advanced 0.24% in 2023 and plunged 95.26% in 2025, its largest moves.
• Year by year, Current Leases stood at $3.4 million in 2022, then grew by 0.24% to $3.4 million in 2023, then tumbled by 45.15% to $1.9 million in 2024, then tumbled by 84.67% to $284000.0 in 2025, then increased by 2.46% to $291000.0 in 2026.
• Per Business Quant, the three latest NMRA Current Leases figures stand at $291000.0 (Q1 2026), $284000.0 (Q4 2025), and $256000.0 (Q3 2025).